Here's is the EMA summary (I believe the full assessment report is not yet public): https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazenec

Here's is the EMA summary (I believe the full assessment report is not yet public): https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu https://www.ema.europa.eu/en/news/ema-recommends-covid-19-va... Key snippet: Most of the participants in these studies were between 18 and 55 years old. There are not yet enough results in older participants (over 55 years old) to provide a figure for how well the vaccine will work in this group. However, protection is expected, given that an immune response is seen in this age group and based on experience with other vaccines; as there is reliable information on safety in this population, EMA’s scientific experts considered that the vaccine can be used in older adults. More information is expected from ongoing studies, which include a higher proportion of elderly participants. I'd assume the EMA's assessment is based on AZ's data and application, rather than on reports from German newspapers or politicians. We can probably all agree with the EMA's assessment that AZ's effectiveness for the elderly is likely but not convincingly demonstrated yet. Based on this it's reasonable for different national EU agencies to give different recommendations for application to the elderly. For instance, in the Netherlands national agency recommends using Pfifer / Moderna for the 65+ and AZ for 65-.